Manmeet S. Soni

Manmeet S. Soni

Chief Operating Officer, Chief Financial Officer and DirectoratSummit Therapeutics· In proxies 2023–2025

Pay in FY2024-80% from the year before · Summit Therapeutics stock +583.7% the same year

Manmeet S. Soni was paid $4.8M in FY2024 (Dec), down 80%. Summit Therapeutics stock rose 583.7% that year.

Pay$100 in the stock at the end of FY22 → $420
Pay is from the Summary Compensation Table of each Summit Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Summit TherapeuticsPublic company · 3 yr
    • Chief Operating Officer, Chief Financial Officer and Director2023 – Present · 3 yrStock in role +294%
  2. Pulse BiosciencesPublic company · 3 yr
    • Lead Independent Director2023 – Present · 3 yrNo stock prices for these years
  3. Pulse Biosciences, Inc.Public company · 9 yr
    • Director2017 – Present · 9 yrNo stock prices for these years
  4. Arena Pharmaceuticals, Inc.Public company · 3 yr
    • Director2018 – 2021 · 3 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards2

  • Pulse BiosciencesLead independent director · 8 yr on the boardIndependentAudit (Chair), Compensation (Chair), Nominating and Corporate Governance (Chair), Strategic Advisory—Paid as an executive
  • Summit TherapeuticsDirector · 4 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?